Solengepras
(CVN424)
PARKINSON’S DISEASE
Potentially a first in class, oral non-dopaminergic therapy for the broad treatment of the signs and symptoms (motor and non-motor) of Parkinson’s disease.
Restores balance by regulating just one side of brain circuitry - the indirect pathway
Solengepras targets GPR6, a target evaluated using NETSseq, presenting a novel point of therapeutic intervention.
By inhibiting GPR6, solengepras aims to reduce periods of symptomatic worsening (“OFF time”), while mitigating the side effects commonly associated with many dopaminergic therapies.
GPR6 is observed in the dopamine receptor D2-positive cells of the medium spiny neuron (“MSN”) indirect pathway, and much lower or absent expression was observed in D1 dopamine receptor-positive cells from the MSN direct pathway, as shown in our NETSseq data below.
Non-specific replacement of dopamine (using L-DOPA or treating patients with drugs that act on dopamine receptors) LACKS the PRECISION to correct this imbalance and can cause “on-target” related side effects.
Solengepras has the potential to provide a novel approach for the treatment of Parkinson's disease with a better tolerability profile than current therapies.
Adjunctive & Monotherapy
Solengepras is being developed for use across the spectrum of Parkinson's disease, both as an adjunctive treatment as well as for monotherapy use. Cerevance is currently conducting a Phase 2 clinical trial of solengepras (ASCEND) as a monotherapy treatment in early, untreated patients with Parkinson's disease. Cerevance has also initiated a pivotal Phase 3 clinical trial of solengepras (ARISE) as an adjunctive treatment in patients experiencing motor fluctuations.
Solengepras - Phase 2 Adjunctive Study
Solengepras 150 mg dose cohort demonstrated a statically significant reduction of 1.3 hours (p=0.02) in average daily OFF time versus placebo after only 27 days of treatment which represented a1.6-hour (p<0.0001) improvement from baseline.
Solengepras 150 mg dose cohort was associated with a dose-dependent improvement trend on the Unified Parkinson’s Disease Rating Scale (UPDRS) Part II score (activities of daily living) versus placebo. Trends to improvement in the UPDRS Part II after treatment with the solengepras 150 mg dose were seen in as little as four weeks, suggesting that solengepras may have broader benefits on the activities of daily living for PD patients beyond motor improvements.
Solengepras did not increase daytime sleepiness, as measured by the Epworth Sleepiness Scale (ESS), and was instead associated with a trend towards reduction in daytime sleepiness with the solengepras 150 mg dose versus placebo.
Solengepras was generally well-tolerated with few adverse events and low rates of dopaminergic adverse events across both dose cohorts.
Solengepras 150 mg dose cohort demonstrated a statically significant reduction of 1.3 hours (p=0.02) in average daily OFF time versus placebo after only 27 days of treatment which represented a1.6-hour (p<0.0001) improvement from baseline.
Solengepras 150 mg dose cohort was associated with a dose-dependent improvement trend on the Unified Parkinson’s Disease Rating Scale (UPDRS) Part II score (activities of daily living) versus placebo. Trends to improvement in the UPDRS Part II after treatment with the solengepras 150 mg dose were seen in as little as four weeks, suggesting that solengepras may have broader benefits on the activities of daily living for PD patients beyond motor improvements.
Solengepras did not increase daytime sleepiness, as measured by the Epworth Sleepiness Scale (ESS), and was instead associated with a trend towards reduction in daytime sleepiness with the solengepras 150 mg dose versus placebo.
Solengepras was generally well-tolerated with few adverse events and low rates of dopaminergic adverse events across both dose cohorts.
Adjunctive & Monotherapy
Solengepras is being developed for use across the spectrum of Parkinson's disease, both as an adjunctive treatment as well as for monotherapy. Cerevance is currently conducting a Phase 2 clinical trial of solengepras (ASCEND) as a monotherapy treatment in early, untreated patients with Parkinson's disease. Cerevance has also initiated a global, pivotal Phase 3 clinical trial of solengepras (ARISE) as an adjunctive treatment in patients with Parkinson's disease experiencing motor fluctuations.
Current
November 18, 2024
Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease
- Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s disease
- ARISE will evaluate the efficacy of solengepras as an adjunctive therapy to levodopa and other background Parkinson’s disease medications
- Company expects to report topline data in the first half of 2026
November 11, 2024
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
- CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosing
- Dose-dependent exposure was observed with evidence of robust brain penetration
- Data supports potential advancement into Phase 2 for neurodegenerative diseases characterized by neuroinflammation such as Frontotemporal Dementia, AmyotrophicLateral Sclerosis, and Alzheimer’s Disease
October 21, 2024
Cerevance Announces Publication of Positive Phase 2 Results of Solengepras for the Treatment of Parkinson’s Disease in eClinical Medicine
Cerevance has published the full results from the Phase 2 clinical trial of solengepras, in eClinicalMedicine, a peer-reviewed journal published by The Lancet Discovery Science Suite. The results demonstrated that solengepras, a potentially first-in-class, oral, once-daily, non-dopaminergic, GPR6 inverse agonist, significantly reduced OFF time in individuals with Parkinson’s disease and was generally well-tolerated.
October 17, 2024
Sarah Sheikh Joins Cerevance’s Board of Directors
Cerevance is pleased to appoint Sarah Isabel Sheikh, M.Sc., B.M. B.Ch., MRCP, to its Board of Directors, effective immediately. Dr. Sheikh holds dual responsibilities at Takeda as the Head of Global Development for all therapeutic areas – Gastrointestinal and Inflammation, Neuroscience, Oncology, Plasma-Derived Therapies, and Vaccines – and as the Head of the Neuroscience Therapeutic Area.
October 8, 2024
Cerevance Achieves Second Milestone in Research Collaboration with Merck
Cerevance announced the achievement of the second milestone in its research collaboration with Merck, known as MSD outside of the United States and Canada. The research collaboration, which was announced in August of 2022, focuses on the identification and validation of novel therapeutic targets for Alzheimer’s disease. The achievement of this milestone triggers a payment from Merck to Cerevance.
August 12, 2024
Cerevance Appoints Sagar Vaidya, M.D., Ph.D., as Chief Medical Officer
Cerevance has appointed Dr. Sagar Vaidya, M.D., Ph.D., as Chief Medical Officer. Dr. Vaidya brings a wealth of experience in drug development, clinical research, and medical affairs, with a distinguished track record in advancing therapeutic programs for severe and life-threatening diseases.
May 2, 2024
Cerevance Achieves First Milestone in Research Collaboration with Merck
Cerevance achieves first milestone in research collaboration with Merck, known as MSD outside of the United States and Canada. The research collaboration, which was announced in August of 2022, focuses on the identification of novel therapeutic targets for Alzheimer’s disease. The achievement of this milestone triggers an undisclosed payment from Merck to Cerevance.
April 25, 2024
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
Cerevance announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised bringing the total Series B-1 raise to $98 million.
April 22, 2024
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
Cerevance announces that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment”.
February 15, 2024
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters. In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist”
November 13, 2023
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
September 19, 2023
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
Cerevance today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.
August 28, 2023
Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023
Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.
July 10, 2023
Cerevance to Present at the Alzheimers Association International Conference
Cerevance to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.
May 16, 2023
Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)
Cerevance to present an oral presentation at the upcomingAmerican Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 – June 2, 2023.
May 9, 2023
Cerevance to Present at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development
Cerevance today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the NextGeneration of Therapeutic Development conference, taking place in British Columbia, Canada, May 15 – 19, 2023.
April 13, 2023
Poster Presentation at the BNA International Festival of Neuroscience
Cerevance today announced a poster presentation at the British Neuroscience Association (BNA) 2023 International Festival of Neuroscience in Brighton, United Kingdom being held April 23-26, 2023
March 21, 2023
Cerevance to Present at Two Medicinal Chemistry Conferences
Cerevance to present at two upcoming medicinal chemistry conferences:
- 7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets held March 27-28 in Cambridge, UK
- Binding Kinetics and Mechanistic PK/PD Modeling in Early Drug Discovery Conference held March 27-28 in Cambridge, UK
March 20, 2023
Cerevance to Present at AD/PD™ 2023 International Conference
- Positive CVN424 Phase 2 data for Parkinson’s disease to be presented
- Presentation of NETSseq platform’s ability to reveal novel targets to inform CNS drug development
- Novel target, CVN417, for the potential treatment of Parkinson’s disease to be disclosed
February 13, 2023
Cerevance Expands Series B Financing with Additional $51 Million
- Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform
- CVN424 for Parkinson’s disease will advance to Phase 2 monotherapy study in Q2 2023
- CVN766 for negative and cognitive symptoms of schizophrenia will advance to Phase 2 study in Q4 2023
- CVN293 for Amyotrophic Lateral Sclerosis will advance to Phase 1 study in Q3 2023
January 27, 2023
Cerevance Announces Publication in Organic Process Research and Development
Cerevance today announced the publication in Organic Process Research and Development entitled, “Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor”.
January 9, 2023
Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia
- CVN766 was well tolerated with no serious adverse events
- CVN766, which has >1000-fold selectivity for the orexin 1 receptor, was well tolerated and showed no evidence of somnolence
- Data supports once a day dosing of CVN766 in future studies
November 30, 2022
Cerevance to Present Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases – Biology and Therapeutics Conference and Publication in Neuropharmacology
- Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform
- Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results in human and mouse cell based and electrophysiology assays relevant to neuroinflammation in neurodegenerative disease
- Data has been concurrently published in the peer-reviewed journal, Neuropharmacology
August 9, 2022
Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
Cerevance today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.
April 19, 2022
Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
Cerevance today announced the appointment of Craig Thompson to chief executive officer. Mr. Thompson brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries to the company.
March 31, 2022
Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
Cerevance today announced the completion of its Phase 2 clinical trial of CVN424, the company’s first-in-class, once-a-day, orally-delivered compound in development for the treatment of Parkinson’s disease.
January 25, 2022
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766
September 8, 2021
Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors
Cerevance today announced the appointment of Mike Poole, M.D., FACP, to Cerevance’s Board of Directors.
February 1, 2021
Cerevance Appoints Carrie Ann Cook as Chief Business Officer
Cerevance, today announced the appointment of Carrie Ann Cook, a global business development executive with more than 20 years of experience in the pharmaceutical industry, as chief business officer
February 1, 2021
Cerevance Appoints Naidong Ye, Ph.D. as Vice President and Head of Chemistry, Manufacturing and Controls
Cerevance today announced the appointment of Naidong Ye, Ph.D., a seasoned chemist with extensive pharmaceutical industry experience, as vice president and head of chemistry, manufacturing and controls (CMC).
December 8, 2020
Cerevance Appoints David Lubner to Board of Directors
Cerevance today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors.
November 16, 2020
Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
Cerevance today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS).
July 21, 2020
Cerevance Expands Series B Financing to $65 Million
Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April.
April 14, 2020
Cerevance Closes $45 Million Series B Financing
Cerevance has closed a Series B financing, bringing in $45 million from new investors including GV (formerly Google Ventures), Bill Gates and Foresite Capital, as well as all of the company’s previous investors...
January 7, 2020
Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors
Dr. Brennan is currently president and chief executive officer of Synlogic, Inc. (Nasdaq:SYBX), a clinical stage biotechnology company applying synthetic biology to beneficial microbes to develop novel, living medicines.
December 17, 2019
Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders
Cerevance has formed a multi-year research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) to identify novel target proteins expressed in the central nervous system and to develop new therapies against them for certain GI disorders.
December 4, 2019
Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease
Cerevance, announced today the initiation of a Phase 2 clinical trial of CVN424, an oral, first-in-class compound that selectively modulates a novel, non-dopaminergic target selectively expressed in an important class of neurons in the striatum.
June 3, 2019
Cerevance Appoints CNS Drug Developer James Summers, Ph.D. as Scientific Advisor
Cerevance has appointed pharmaceutical industry veteran, James Summers, Ph.D., as a key scientific advisor to guide the company in its drug discovery and development efforts. Dr. Summers brings extensive experience in the discovery of...
April 30, 2019
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has successfully completed its Phase 1 clinical trial of CVN424, the company’s first-in-class, orally-delivered compound in development for the treatment of Parkinson’s disease.
April 16, 2019
Cerevance Appoints Industry Veteran Roland Bürli, Ph.D. as Vice President of Drug Discovery
Roland Bürli, Ph.D. as Vice President of Drug Discovery brings expertise in preclinical drug discovery, specializing in medicinal and synthetic chemistry, with a proven track record from hit identification through lead optimization, having led efforts that discovered six pre-clinical candidate molecules, including a program now in Phase II.
March 5, 2019
Industry Central Nervous System Specialist Lee Dawson, Ph.D. Joins Cerevance as VP of Neuroscience
Dawson brings 25 years of career experience spearheading drug discovery and development across companies based in the United States, Japan and the United Kingdom. Most recently, he served as Vice President of CNS drug development at Astex Pharmaceuticals, where he established and developed their global neuroscience research strategy.
October 9, 2018
Cerevance Appoints Ted Hibben as Chief Business Officer
A twenty-year biotechnology industry veteran, Mr. Hibben has formed over $2 billion in platform and product-based R&D collaborations. Prior to joining Cerevance, Mr. Hibben served as Chief Business Officer at Catabasis where he led partnering activities.
September 25, 2018
Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease
Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease.
February 21, 2018
Cerevance Kicks Off 2018 with Additional $10 Million of Infusions
Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has received an additional equity investment as well as a non-dilutive cash payment in the first six weeks of 2018 totaling more than $10 million.
November 27, 2017
Cerevance Appoints David H. Margolin, M.D., Ph.D., as Senior Vice President of Clinical and Translational Medicine
Prior to joining Cerevance, Dr. Margolin served in several leadership roles at Sanofi-Genzyme over a 14-year period. There, he leveraged his expertise in designing and leading translational medicine initiatives as well as clinical trials from phase 1 to phase 4 across various neurologic and rare disease indications...
October 24, 2017
Trailblazer in Molecular Genetics and Neuroscience, Jeremy Nathans, M.D., Ph.D., to Advise Cerevance
Dr. Nathans is Professor of Molecular Biology and Genetics, Neuroscience and Ophthalmology at the Johns Hopkins University School of Medicine in Baltimore, Maryland, where his research focuses on molecular mechanisms of visual system development, function, and disease. He is also an Investigator in the Howard Hughes Medical Institute.
October 17, 2017
Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University
Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue
October 12, 2017
Harvard’s Rudolph Tanzi, Ph.D., a Leader in Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board
Cerevance, a drug discovery and development company focused on brain diseases, today announced that Rudolph Tanzi, Ph.D., has joined the company as a senior-level scientific advisor.
October 5, 2017
Stanford Neuroscientist, Robert Malenka, M.D., Ph.D., to Advise Cerevance
Cerevance, a drug discovery and development company, today announced that Robert Malenka, M.D., Ph.D., has joined the company as a senior-level scientific advisor. Dr. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences at Stanford University.
May 3, 2017
Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia
The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance.
December 2, 2016
Cerevance Launched With New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases
- Takeda and Lightstone Ventures Participate in Series A Financing
- Former Takeda Cambridge UK employees, CNS programs moved to create turn-key discovery capabilities
Current
September 23, 2024
Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
June 18, 2024
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
May 20, 2024
Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention
May 9, 2024
Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders
April 29, 2024
Cerevance to Present at RBC Capital Markets 2024 Global Healthcare Conference
April 29, 2024
Cerevance to Participate at Wells Fargo Virtual Private Biotech Symposium
April 17, 2024
Cerevance Presents at 35th Symposium on Medicinal Chemistry in Eastern England
April 2, 2024
Cerevance to Participate at the 23rd Annual Needham Virtual Health Care Conference
March 13, 2024
Cerevance Announces Presentation at Alzheimer’s Research UK Conference
February 27, 2024
Cerevance Announces Presentation at AD/PD™ 2024 International Conference
February 22, 2024
Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference
December 5, 2023
Cerevance to Participate in Fireside Chat at the 2023 RBC Capital Markets Healthcare Private Company Virtual Conference
November 28, 2023
Cerevance Announces Presentation at the 34th International Symposium on ALS/MND
November 7, 2023
Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting
November 1, 2023
Cerevance to Participate in the Truist Securities BioPharma Symposium
October 25, 2023
Cerevance to Participate at the Wells Fargo 2023 Private Biotech Symposium
October 18, 2023
Cerevance to Participate at the Leerink Biopharma Private Company Connect
October 10, 2023
Cerevance to Participate at the 3rd Annual Needham Biotech Private Company Forum. Company management will host one-on-one meetings during the conference.
October 4, 2023
Cerevance to Participate at the 2023 Life Sciences Private Company Showcase
October 2, 2023
Cerevance to Present at the 36th European College of Neuropsychopharmacology Congress
September 5, 2023
Cerevance to Present During the 6th Annual LSX World Congress USA
August 31, 2023
22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium
July 10, 2023
Alzheimers Association International Conference
June 28, 2023
XVI European Meeting on Glial Cells in Health and Disease
June 26, 2023
Gordon Research Conference
May 16, 2023
Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)
May 9, 2023
Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development
May 8, 2023
2023 RBC Capital Markets Global Healthcare Conference
April 13, 2023
BNA International Festival of Neuroscience
April 10, 2023
Needham Healthcare Conference
March 27, 2023
Chief Medical Officer Summit 360˚
March 21, 2023
Two Medicinal Chemistry Conferences
March 20, 2023
AD/PD™ 2023 International Conference
March 7, 2023
Alzheimer’s Research UK Conference 2023
January 24, 2023
SVB Global Biopharma Conference
December 7, 2022
Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference
November 30, 2022
Biology and Therapeutics Conference
June 16, 2022
5th Annual LSX World Congress USA
June 8, 2022
2022 BIO International Convention
The ASCEND Parkinson’s Disease Clinical Research Study
The ASCEND clinical study is evaluating whether CVN424, an investigational drug, is safe and effective in improving the motor and non-motor symptoms of Parkinson’s disease.
